Dr Sarah Stone
Bioanalytical - Biacore
Dr. Sarah Stone joined Sartorius Stedim BioOutsource Ltd in 2012, following a successful academic career, and quickly became a key member of the biosimilars department. During a period of rapid growth for the company, Sarah developed expertise in the characterization of biosimilar monoclonal antibody-based therapies for some of the blockbuster molecules, including Rituximab, Etanercept, Adalimumab, Trastuzumab and Bevacizumab; using SPR-based technologies, namely the Biacore T200 and Biacore 4000 systems.
Currently, Sarah leads the Biacore department at BioOutsource, working on a wide range of commercial and R&D projects to develop a range of new Biacore assays. Although initially focussed on characterization of Fc binding characteristics, the work of the department has increasingly started to focus on the challenges of analysing the high affinity Fab-antigen interaction which can be particularly problematic for receptor-Fc fusion proteins and affinity matured molecules.